• In oncology, immunotherapy was celebrated as one of the greatest innovations in recent history in oncology treatment, and the question remains: What’s next for cancer treatment?
• Now, there is tremendous investment in pursuing additional innovation – new targets, new ADCs, platform-based drug design, and cell therapies – all of which is seeking to increase options and improve outcomes for cancer patients.
• This report dives into these trends in oncology clinical development, with focus on the clinical-stage pipeline beyond cell therapy to home in on ADCs, antibodies, and T cell Engagers (TCEs).
• This report contains 1) trends in each modality, 2) insights for top companies, and 3) lists of companies with clinical-stage assets for each modality

 

Each purchase includes up to 4 hours of dedicated time from one of the Axiom team, it’s a great way to gain tailored and actionable insights relevant for your company!